Latest Breaking News On - Prescription drug user fee act however - Page 1 : comparemela.com

The Food and Drug Administration (FDA) will not be meeting the Jan. 12, 2024 approval deadline for zolbetuximab to treat certain patients with gastric or gastroesophageal junction adenocarcinoma.

Kohei shitaraMoitreyee chatterjee kishoreDrug administrationNational cancer center hospitalPrescription drug user fee act howeverNational cancer center hospital eastGastric cancerGastroesophageal junction adenocarcinoma